Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals, Ltd. is a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for rare and orphan diseases. Headquartered in Ashburn, Virginia, United States, the company's mission is to address critical, unmet medical needs for patients, their families, communities, and care teams by bringing hope where there is currently none.

The company's innovative pipeline focuses on a broad range of rare and orphan indications, particularly dermatological conditions. Its lead product candidate, QRX003, is a topical lotion currently in late-stage clinical trials for the treatment of Netherton Syndrome, a rare hereditary skin disease. Quoin Pharmaceuticals is also developing other product candidates, including QRX004 for recessive dystrophic epidermolysis bullosa and QRX008 for scleroderma, with additional indications such as Peeling Skin Syndrome, Ichthyosis, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas, and SAM Syndrome also being targeted.

In recent news, the U.S. FDA granted Fast Track Designation for QRX003 for Netherton Syndrome on March 11, 2026, facilitating its development and expediting regulatory review. The company is targeting approval for QRX003 in 2027 and has reported a private placement financing of up to $104.5 million in its Q4 and full-year 2025 updates. Led by Co-Founder, Chairman, and CEO Dr. Michael Myers, alongside Co-Founder and COO Denise Carter, Quoin Pharmaceuticals plans to establish commercial infrastructure in the U.S., Western Europe, and Japan, complemented by strategic commercial agreements spanning 61 countries.